Genting Xinyao will hold an online investor conference for the company's new strategy launch

SHANGHAI, Dec.
30, 2022 /PRNewswire/ -- Genting New Yao (HKEX 1952.
HK), a biopharmaceutical company focused on the development and commercialization of innovative drugs and vaccines, is committed to meeting unmet medical needs in the Asia-Pacific market, announcing that it will host a virtual investor conference
for the launch of its new strategy.
Mr.
Law Yongqing, Chief Executive Officer of the Company, and Mr.
He Ying, President and Chief Financial Officer of the Company, will attend the meeting to introduce the future strategic development direction of the Company and answer questions
.

The conference will be divided into two events, Chinese and English, which will be held on January 3, 2023 at 8 p.
m.
Beijing time (7 a.
m.
EST) on the same day; Chinese session will be held
on January 4, 2023 at 10 a.
m.
Beijing time (January 3 at 9 p.
m.
ET).

Meeting Information:

English Conference: Meeting Time: January 3, 2023 at 8 p.
m.
(Beijing time)
Registration link:
_istranslated="1"> participants need to register prior to the conference call
。

Link to live stream of the meeting:

At the same time, participants can dial in to the conference call using the following dial-in information:

Chinese meeting: meeting time: January 4, 2023 at 10 a.
m.
(Beijing time) Conference live broadcast link:
https://s.
comein.
cn/AhhxE (Jinmen Finance)

At the same time, participants can dial in to the conference call using the following dial-in information:

After the English session, you can listen to the English conference replay
by visiting the Genting New Yaos website (

About Genting Xinyao

Genting Xinyao is a biopharmaceutical company focused on the development and commercialization of innovative drugs and vaccines, focusing on meeting unmet medical needs
in the Asian market.
Genting Xinyao's management team has deep expertise and extensive experience
in high-quality clinical development, drug administration, chemical manufacturing and control (CMC), business development and operations in China and leading global pharmaceutical companies.
Genting Xinyao has created a number of drug portfolios that have the potential to become firsts of their kind or best-in-class in the world, most of which are in the advanced stages
of clinical trials.
The company's therapeutic areas include oncology, autoimmune diseases, heart and kidney diseases, infectious and infectious diseases
.
For more information, visit the company website: www.
everestmedicines.
com
.

Forward-Looking Statements:

The information contained in this press release may contain certain forward-looking statements based on the current beliefs, beliefs and expectations of the Company or management with respect to the Company's business operations and financial condition at the time of making such statements, and may be expressed by the words "will," "anticipate," "forecast," "expect," "intend," "plan," "believe," "estimate," "believe" and other similar words
.
These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict
.
As a result, actual results may differ
materially from the information contained in forward-looking statements due to various factors and assumptions, including future changes and developments in our business, competitive environment, political, economic, legal and social conditions.
The Company and its subsidiaries, directors, officers, consultants and agents undertake and undertake no obligation to update the forward-looking statements contained in this press release to reflect the latest information, future projects or circumstances after the date of this press release, except as required
by law.